SCHEMBL4920060

SCHEMBL4920060

CS(=O)(=O)Nc1cccc(Nc2nc(Oc3ccc(F)cc3)c3nc[nH]c3n2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 2/20 0.43
PTK2 Q05397 3/20 0.42
CDK1 P06493 1/20 0.42
CYP1A2 P05177 4/20 0.42
CYP3A4 P08684 4/20 0.42
CYP2D6 P10635 4/20 0.42
LMNA P02545 3/20 0.42
USP2 O75604 2/20 0.42
CLK4 Q9HAZ1 2/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
F2 P00734 1/20 0.41
F10 P00742 1/20 0.41
KDR P35968 2/20 0.39
TSHR P16473 3/20 0.39
ALDH1A1 P00352 2/20 0.39
ALOX15 P16050 2/20 0.39
HSD17B10 Q99714 2/20 0.39
MAPT P10636 2/20 0.39
HPGD P15428 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4917058 0.81 PTK2 (0.47) PTK2CDK1CYP1A2CYP3A4LMNA
SCHEMBL4917834 0.80 NPC1 (0.46) PTK2CDK1CYP1A2CYP3A4CYP2D6
SCHEMBL4649832 0.79 PTK2 (0.50) PTK2CYP1A2CYP3A4CYP2D6USP2
SCHEMBL4919889 0.78 CDK2 (0.43) PTK2CDK1KDRBRD4EPHB4
SCHEMBL4916505 0.77 CDK2 (0.58) CDK1
SCHEMBL4916480 0.76 BRD4 (0.43) PTK2BRD4EGFR
SCHEMBL4914661 0.76 PTK2 (0.43) PTK2CDK1KDRBRD4EPHB4
SCHEMBL4920902 0.75 PTK2 (0.42) PTK2CYP1A2CYP3A4CYP2D6LMNA
SCHEMBL4916387 0.74 PTK2 (0.41) PTK2CYP1A2CYP3A4ALDH1A1ALOX15
SCHEMBL4909631 0.74 PTK2 (0.41) PTK2CYP1A2CYP3A4ALDH1A1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080261973-A1 Sulphonamidoaniline Derivatives Being Janus Kinase Inhibitors NOVARTIS AG (CH) 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261973-A1 Sulphonamidoaniline Derivatives Being Janus Kinase Inhibitors GRK4, JAK2, ALK SCN9A 1130/4885PTK2 1036/4885CDK1 460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.